悪性中皮腫治療市場- 世界の産業規模、動向、機会、予測、2018年～2028年、薬剤タイプ別、投与経路別、エンドユーザー別、地域別、競合

悪性中皮腫治療の世界市場は、2022年に2億4,322万米ドルと評価され、2028年までのCAGRは6.25%で、予測期間中に目覚ましい成長を予測しています。

悪性中皮腫は、胸部、腹部、心臓を覆う中皮細胞を侵すまれで侵攻性のがんです。この疾患は主にアスベスト曝露と関連しており、その予後は暗いことが多いです。しかし、最近の腫瘍学と製薬業界の進歩により、悪性中皮腫治療の市場が拡大しています。

悪性中皮腫は依然として比較的まれな疾患であるが、その発生率は世界的に増加しています。これは診断の遅れやアスベスト曝露に伴う長い潜伏期間が一因です。バイオマーカー同定や画像診断技術などの診断技術の向上により、中皮腫の早期発見が可能となっています。早期診断は効果的な治療に不可欠です。製薬業界では、悪性中皮腫に対する新しい治療法や治療アプローチが開発されています。これらの治療法には免疫療法、標的療法、遺伝子療法などがあり、より良い治療結果が期待されています。多くの国の政府はアスベストの使用を制限する規制を導入しており、将来的に中皮腫の発生を減少させる可能性があります。さらに、ヘルスケア改革は罹患者の治療へのアクセスを改善することを目的としています。

世界の悪性中皮腫治療市場は、診断と治療の選択肢の進歩に牽引され、著しい成長を遂げています。この侵攻性のがんと診断された患者は、革新的な治療法と研究の進展により、以前よりも多くの希望を持てるようになりました。課題は依然として存在するもの、製薬企業、研究機関、支援団体の献身的な努力により、悪性中皮腫に罹患した患者にとって明るい未来が約束されています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 悪性中皮腫治療の世界市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤タイプ別（ペメトレキセド、シスプラチン、カルボプラチン、ゲムシタビン、ビノレルビン、その他）
  • 投与経路別（経口、非経口）
  • エンドユーザー別（病院、がんセンター、その他）
  • 地域別
  • 企業別（主要5社シェア）
• 市場マップ
  • 薬剤タイプ別
  • 投与経路別
  • エンドユーザー別
  • 地域別

第6章 北米の悪性中皮腫治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤タイプ別
  • 投与経路別
  • エンドユーザー別
  • 国別

第7章 欧州の悪性中皮腫治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤タイプ別
  • 投与経路別
  • エンドユーザー別
  • 国別

第8章 アジア太平洋地域の悪性中皮腫治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤タイプ別
  • 投与経路別
  • エンドユーザー別
  • 国別

第9章 南米の悪性中皮腫治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤タイプ別
  • 投与経路別
  • エンドユーザー別
  • 国別

第10章 中東・アフリカの悪性中皮腫治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤タイプ別
  • 投与経路別
  • 投与経路別
  • エンドユーザー別
  • 国別

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の展開
• 合併・買収
• 技術発表

第13章 競合情勢

• Dr. Reddy's Laboratories Ltd.
  • Business Overview
  • Patient Offerings
  • Recent Developments
  • Key Personnel
  • SWOT Analysis
• Wellona Pharmaceuticals pvt ltd.
• Bristol-Myers Squibb Company
• Novocure GmbH
• Eli Lilly and Company
• Merck Kgaa
• Manus Aktteva Biopharma LLP
• Pfizer inc.
• Ono Pharmaceuticals Co., Ltd

第14章 戦略的提言

会社概要・免責事項

Global Malignant Mesothelioma Therapeutics Market has valued at USD 243.22 Million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.25% through 2028. Malignant mesothelioma is a rare and aggressive form of cancer that affects the mesothelial cells lining the chest, abdomen, and heart. This disease is primarily associated with asbestos exposure, and its prognosis is often bleak. However, recent advancements in the field of oncology and the pharmaceutical industry have given rise to a growing market for malignant mesothelioma therapeutics.

While malignant mesothelioma remains relatively rare, its incidence has been increasing globally. This is partly due to delayed diagnoses and the long latency period associated with asbestos exposure. Improved diagnostic techniques, including biomarker identification and imaging technologies, have enabled earlier detection of mesothelioma. Early diagnosis is critical for effective treatment. The pharmaceutical industry has witnessed the development of novel therapies and treatment approaches for malignant mesothelioma. These include immunotherapy, targeted therapy, and gene therapy, which offer hope for better outcomes. Governments in many countries have introduced regulations to restrict asbestos use, which can potentially reduce future cases of mesothelioma. Additionally, healthcare reforms aim to improve access to treatment for affected individuals.

The global malignant mesothelioma therapeutics market is witnessing significant growth, driven by advancements in diagnosis and treatment options. Patients diagnosed with this aggressive cancer now have more hope than ever before, thanks to innovative therapies and a growing body of research. While challenges still exist, the dedication of pharmaceutical companies, research institutions, and advocacy groups promises a brighter future for those affected by malignant mesothelioma.

Key Market Drivers

Increasing Incidence Rates is Driving the Global Malignant Mesothelioma Therapeutics Market

Malignant mesothelioma, a rare and aggressive cancer primarily associated with asbestos exposure, has been on the rise globally in recent years. This alarming increase in incidence rates has spurred significant research and development efforts in the field of mesothelioma therapeutics. As more individuals are diagnosed with this devastating disease, the demand for effective treatment options is growing, driving the global malignant mesothelioma therapeutics market forward.

Over the past few decades, the incidence rates of malignant mesothelioma have seen a concerning increase. This can be attributed to several factors. Many individuals who were exposed to asbestos in the mid-20th century are now being diagnosed with mesothelioma as the disease takes years to manifest. This prolonged exposure is contributing to a higher incidence rate among older generations. People who were not directly involved in industries with high asbestos exposure risk but had contact with asbestos-exposed individuals are also being diagnosed with mesothelioma. This secondary exposure is often underestimated and contributes to the rising incidence rates. Despite awareness of the health hazards of asbestos, some countries continue to import and use asbestos-containing products, leading to ongoing exposure and increased mesothelioma cases. Asbestos can become airborne during the demolition or renovation of buildings containing asbestos materials. This environmental exposure has led to cases of mesothelioma among individuals who never worked directly with asbestos.

The increasing incidence of malignant mesothelioma has created a growing market for mesothelioma therapeutics. Pharmaceutical companies, research institutions, and healthcare providers are focusing their efforts on developing innovative treatment options. Research into novel drug therapies, immunotherapies, and targeted therapies for mesothelioma has intensified. These treatments aim to improve survival rates and enhance the quality of life for patients. The rising incidence of mesothelioma has facilitated larger and more diverse patient pools for clinical trials, accelerating the development and approval of new treatments. In addition to curative therapies, there is a growing demand for palliative care options to manage symptoms and improve the comfort and well-being of mesothelioma patients. Efforts to develop effective screening and early detection methods for mesothelioma are ongoing, with the goal of diagnosing the disease at a more treatable stage.

Growing Research and Development Efforts is Driving the Global Malignant Mesothelioma Therapeutics Market

Over the past decade, there has been a noticeable resurgence in research and development efforts targeting malignant mesothelioma. Several factors have contributed to this renaissance.

Heightened awareness of the dangers of asbestos exposure has led to greater attention on the disease. Advocacy groups, healthcare organizations, and regulatory agencies have been instrumental in raising awareness and pushing for research funding. Advances in molecular biology and genomics have enabled researchers to better understand the underlying mechanisms of malignant mesothelioma. This knowledge has paved the way for targeted therapies and personalized treatment approaches. Researchers and pharmaceutical companies have been collaborating more closely, resulting in increased funding for mesothelioma research. The U.S. National Cancer Institute and various foundations have also played significant roles in financing studies focused on finding effective therapeutics. The number of clinical trials for malignant mesothelioma has surged. These trials allow researchers to test innovative treatments, assess their safety and efficacy, and provide patients with access to cutting-edge therapies.

The concerted efforts of the scientific community have yielded promising developments in the field of malignant mesothelioma therapeutics. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have shown promise in treating malignant mesothelioma by enhancing the body's immune response against cancer cells. Researchers have identified specific molecular targets, such as the BAP1 gene mutation, and are developing drugs that can target these anomalies more precisely. Gene therapy approaches are being explored to deliver therapeutic genes directly to cancer cells, potentially halting their growth or inducing cell death. Improved diagnostic tools and biomarker identification are enhancing early detection, allowing for more timely intervention.

Key Market Challenges

Limited Awareness and Early Diagnosis

One of the most significant challenges in managing malignant mesothelioma is the lack of awareness about the disease among the general population and healthcare professionals. This results in delayed diagnoses, often when the cancer has reached an advanced stage, making it difficult to treat effectively. Early diagnosis is critical for better prognosis, but the absence of routine screening and the non-specific symptoms of mesothelioma contribute to late detection.

Complex Disease Biology

Malignant mesothelioma is a complex disease with intricate biology. Understanding its progression and developing effective treatments is challenging due to the various subtypes of mesothelioma, each with unique characteristics and behaviors. Tailoring treatments to the specific subtype and stage of the disease is essential, but it requires in-depth research and personalized approaches.

Limited Treatment Options

The current treatment options for malignant mesothelioma are limited. Surgery, chemotherapy, and radiation therapy are the primary approaches, but they often provide only palliative relief. Targeted therapies and immunotherapies, which have shown promise in other cancer types, are still in the experimental stages for mesothelioma, and their effectiveness remains uncertain.

Resistance to Chemotherapy

Chemotherapy is a common treatment option for malignant mesothelioma, but the disease often develops resistance to chemotherapy drugs over time. This resistance poses a significant challenge in maintaining the effectiveness of chemotherapy as a treatment option. Finding new drugs or drug combinations that can overcome resistance is an ongoing struggle.

High Costs of Research and Development

Developing new therapies for malignant mesothelioma is an expensive and time-consuming process. Pharmaceutical companies may be hesitant to invest in research and development for a disease with a relatively small patient population compared to more common cancers. This limited financial incentive can slow down progress in developing innovative treatments.

Regulatory Hurdles

The approval process for new cancer treatments involves rigorous clinical trials and regulatory approvals, which can be lengthy and challenging to navigate. Meeting the stringent requirements of regulatory agencies like the U.S. Food and Drug Administration (FDA) is essential but can be a bottleneck in bringing new therapies to market.

Access to Treatment

Access to cutting-edge treatments and clinical trials can be uneven, with patients in certain regions or with limited financial resources facing barriers to receiving the latest therapies. Ensuring equitable access to promising treatments for all patients is a significant challenge in improving outcomes for malignant mesothelioma.

Shortage of Specialized Healthcare Professionals

The management of malignant mesothelioma requires a multidisciplinary approach involving oncologists, surgeons, radiologists, and other healthcare professionals with expertise in this rare cancer. The shortage of specialized healthcare providers can hinder the delivery of comprehensive care and access to the latest treatments.

Key Market Trends

Technological Advancements

The global healthcare landscape has witnessed remarkable technological advancements in recent years. These innovations have not only revolutionized patient care but also had a profound impact on the development of new therapies for various diseases, including rare and aggressive conditions like malignant mesothelioma. Malignant mesothelioma is a challenging cancer to treat, primarily caused by asbestos exposure. However, recent technological breakthroughs are driving progress in the field of mesothelioma therapeutics, offering hope to patients and increasing the overall market potential.

One of the key challenges in treating malignant mesothelioma is its late-stage diagnosis. However, advancements in imaging technology, such as high-resolution computed tomography (HRCT) scans and positron emission tomography (PET) scans, have significantly improved early detection. These techniques allow for the identification of mesothelioma at a stage where surgical intervention is more viable, increasing the chances of successful treatment. Recent developments in molecular biology and genomics have paved the way for personalized medicine in mesothelioma treatment. Researchers can now identify specific genetic mutations and biomarkers associated with the disease. This has led to the development of targeted therapies that focus on inhibiting the growth of cancer cells by blocking specific molecular pathways. These treatments are not only more effective but also have fewer side effects compared to traditional chemotherapy.

Immunotherapy has emerged as a promising treatment option for malignant mesothelioma. Checkpoint inhibitors, such as pembrolizumab and nivolumab, have shown potential in clinical trials by boosting the body's immune system to fight cancer cells. Technological advancements in immunotherapy research and development have led to more precise therapies, enhancing their effectiveness and reducing adverse effects. Advancements in surgical technology have led to the development of minimally invasive procedures, such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgery. These techniques allow for smaller incisions, shorter hospital stays, and faster recovery times for patients undergoing surgery for mesothelioma. Data analytics and AI are playing a crucial role in mesothelioma research and treatment. AI algorithms can analyze vast amounts of patient data, identify patterns, and predict treatment outcomes more accurately. This assists healthcare professionals in making informed decisions about the most suitable treatment options for individual patients.

Segmental Insights

Drug Type Insights

Based on the category of Drug Type, Pemetrexed emerged as the dominant player in the global market for Malignant Mesothelioma Therapeutics in 2022. Pemetrexed, an antifolate chemotherapy drug, was first approved by the U.S. Food and Drug Administration (FDA) in 2004 for the treatment of malignant pleural mesothelioma, a particularly aggressive subtype of mesothelioma. Since then, it has gained widespread acceptance and usage among oncologists due to its efficacy and relatively manageable side effects. Clinical trials and real-world studies have consistently demonstrated Pemetrexed's effectiveness in extending the survival and improving the quality of life of mesothelioma patients. It has shown superior outcomes when used in combination with cisplatin, another chemotherapy agent commonly used in mesothelioma treatment. Pemetrexed's initial FDA approval was followed by several additional approvals for various stages of mesothelioma and other cancers, solidifying its role as a versatile and trusted treatment option. Compared to some other chemotherapy drugs, Pemetrexed tends to cause fewer severe side effects, making it more tolerable for patients undergoing treatment. This has contributed to its widespread adoption.

End User Insights

The Hospital segment is projected to experience rapid growth during the forecast period. Hospitals have state-of-the-art diagnostic facilities that can accurately stage the disease and determine the most appropriate treatment approach. This is crucial in guiding the treatment decisions for malignant mesothelioma, as the disease's stage significantly influences the prognosis and therapeutic options. Malignant mesothelioma requires a multidisciplinary approach to treatment, involving medical oncologists, surgical oncologists, radiation oncologists, pulmonologists, pathologists, and more. Hospitals are well-equipped to provide access to a diverse team of specialists who can collaborate to develop individualized treatment plans for each patient. Many hospitals are at the forefront of malignant mesothelioma research, conducting clinical trials to evaluate novel therapies, immunotherapies, and targeted treatments. Patients treated at hospitals may have access to these groundbreaking trials, giving them the opportunity to receive experimental treatments that could potentially improve outcomes.

Regional Insights

North America emerged as the dominant player in the global Malignant Mesothelioma Therapeutics market in 2022, holding the largest market share in terms of value. One of the primary factors contributing to North America's dominance in the malignant mesothelioma therapeutics market is the region's high incidence rates of mesothelioma. The United States, in particular, has a long history of asbestos use in various industries, such as construction and manufacturing, which has resulted in a substantial number of asbestos-related diseases, including mesothelioma. Additionally, Canada has also been a major producer and exporter of asbestos, further contributing to the region's high incidence rates. North America boasts a robust healthcare infrastructure that includes leading cancer centers, research institutions, and pharmaceutical companies. These organizations collaborate to develop innovative treatment options and conduct clinical trials for malignant mesothelioma. Their collective efforts have resulted in the discovery of new therapeutic approaches, leading to improved outcomes for patients. The pharmaceutical and biotechnology industries in North America have made substantial investments in researching malignant mesothelioma and developing targeted therapies. These investments have led to the creation of novel drugs that specifically target the mechanisms responsible for mesothelioma's growth and progression. The development of these cutting-edge treatments has given North America a competitive edge in the global market.

Key Market Players

Dr. Reddy's Laboratories Ltd.

Wellona Pharmaceuticals pvt ltd.

Bristol-Myers Squibb Company

Novocure GmbH

Eli Lilly and Company

Merck Kgaa

Manus Aktteva Biopharma LLP

Pfizer inc.

Ono Pharmaceuticals Co., Ltd

Report Scope:

In this report, the Global Malignant Mesothelioma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Malignant Mesothelioma Therapeutics Market, By Drug Type:

• Pemetrexed
• Cisplatin
• Carboplatin
• Gemcitabine
• Vinorelbine
• Others

Malignant Mesothelioma Therapeutics Market, By Route of Administration:

• Oral
• Parenteral

Malignant Mesothelioma Therapeutics Market, By End user:

• Hospitals
• Cancer Centers
• Others

Malignant Mesothelioma Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Malignant Mesothelioma Therapeutics Market.

Available Customizations:

• Global Malignant Mesothelioma Therapeutics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Malignant Mesothelioma Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Others)
  • 5.2.2. By Route of Administration (Oral, Parenteral)
  • 5.2.3. By End user (Hospitals, Cancer Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (Shares of Top 5 Market Players)
• 5.3. Market Map
  • 5.3.1. By Drug Type
  • 5.3.2. By Route of Administration
  • 5.3.3. By End user
  • 5.3.4. By Region

6. North America Malignant Mesothelioma Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By End user
  • 6.2.4. By Country
    • 6.2.4.1. United States Malignant Mesothelioma Therapeutics Market Outlook
      • 6.2.4.1.1. Market Size & Forecast
      • 6.2.4.1.1.1. By Value
      • 6.2.4.1.2. Market Share & Forecast
      • 6.2.4.1.2.1. By Drug Type
      • 6.2.4.1.2.2. By Route of Administration
      • 6.2.4.1.2.3. By End User
    • 6.2.4.2. Canada Malignant Mesothelioma Therapeutics Market Outlook
      • 6.2.4.2.1. Market Size & Forecast
      • 6.2.4.2.1.1. By Value
      • 6.2.4.2.2. Market Share & Forecast
      • 6.2.4.2.2.1. By Drug Type
      • 6.2.4.2.2.2. By Route of Administration
      • 6.2.4.2.2.3. By End User
    • 6.2.4.3. Mexico Malignant Mesothelioma Therapeutics Market Outlook
      • 6.2.4.3.1. Market Size & Forecast
      • 6.2.4.3.1.1. By Value
      • 6.2.4.3.2. Market Share & Forecast
      • 6.2.4.3.2.1. By Drug Type
      • 6.2.4.3.2.2. By Route of Administration
      • 6.2.4.3.2.3. By End User

7. Europe Malignant Mesothelioma Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By End User
  • 7.2.4. By Country
    • 7.2.4.1. France Malignant Mesothelioma Therapeutics Market Outlook
      • 7.2.4.1.1. Market Size & Forecast
      • 7.2.4.1.1.1. By Value
      • 7.2.4.1.2. Market Share & Forecast
      • 7.2.4.1.2.1. By Drug Type
      • 7.2.4.1.2.2. By Route of Administration
      • 7.2.4.1.2.3. By End User
    • 7.2.4.2. Germany Malignant Mesothelioma Therapeutics Market Outlook
      • 7.2.4.2.1. Market Size & Forecast
      • 7.2.4.2.1.1. By Value
      • 7.2.4.2.2. Market Share & Forecast
      • 7.2.4.2.2.1. By Drug Type
      • 7.2.4.2.2.2. By Route of Administration
      • 7.2.4.2.2.3. By End User
    • 7.2.4.3. United Kingdom Malignant Mesothelioma Therapeutics Market Outlook
      • 7.2.4.3.1. Market Size & Forecast
      • 7.2.4.3.1.1. By Value
      • 7.2.4.3.2. Market Share & Forecast
      • 7.2.4.3.2.1. By Drug Type
      • 7.2.4.3.2.2. By Route of Administration
      • 7.2.4.3.2.3. By End User
    • 7.2.4.4. Italy Malignant Mesothelioma Therapeutics Market Outlook
      • 7.2.4.4.1. Market Size & Forecast
      • 7.2.4.4.1.1. By Value
      • 7.2.4.4.2. Market Share & Forecast
      • 7.2.4.4.2.1. By Drug Type
      • 7.2.4.4.2.2. By Route of Administration
      • 7.2.4.4.2.3. By End User
    • 7.2.4.5. Spain Malignant Mesothelioma Therapeutics Market Outlook
      • 7.2.4.5.1. Market Size & Forecast
      • 7.2.4.5.1.1. By Value
      • 7.2.4.5.2. Market Share & Forecast
      • 7.2.4.5.2.1. By Drug Type
      • 7.2.4.5.2.2. By Route of Administration
      • 7.2.4.5.2.3. By End User

8. Asia Pacific Malignant Mesothelioma Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By End User
  • 8.2.4. By Country
    • 8.2.4.1. China Malignant Mesothelioma Therapeutics Market Outlook
      • 8.2.4.1.1. Market Size & Forecast
      • 8.2.4.1.1.1. By Value
      • 8.2.4.1.2. Market Share & Forecast
      • 8.2.4.1.2.1. By Drug Type
      • 8.2.4.1.2.2. By Route of Administration
      • 8.2.4.1.2.3. By End User
    • 8.2.4.2. India Malignant Mesothelioma Therapeutics Market Outlook
      • 8.2.4.2.1. Market Size & Forecast
      • 8.2.4.2.1.1. By Value
      • 8.2.4.2.2. Market Share & Forecast
      • 8.2.4.2.2.1. By Drug Type
      • 8.2.4.2.2.2. By Route of Administration
      • 8.2.4.2.2.3. By End User
    • 8.2.4.3. South Korea Malignant Mesothelioma Therapeutics Market Outlook
      • 8.2.4.3.1. Market Size & Forecast
      • 8.2.4.3.1.1. By Value
      • 8.2.4.3.2. Market Share & Forecast
      • 8.2.4.3.2.1. By Drug Type
      • 8.2.4.3.2.2. By Route of Administration
      • 8.2.4.3.2.3. By End User
    • 8.2.4.4. Japan Malignant Mesothelioma Therapeutics Market Outlook
      • 8.2.4.4.1. Market Size & Forecast
      • 8.2.4.4.1.1. By Value
      • 8.2.4.4.2. Market Share & Forecast
      • 8.2.4.4.2.1. By Drug Type
      • 8.2.4.4.2.2. By Route of Administration
      • 8.2.4.4.2.3. By End User
    • 8.2.4.5. Australia Malignant Mesothelioma Therapeutics Market Outlook
      • 8.2.4.5.1. Market Size & Forecast
      • 8.2.4.5.1.1. By Value
      • 8.2.4.5.2. Market Share & Forecast
      • 8.2.4.5.2.1. By Drug Type
      • 8.2.4.5.2.2. By Route of Administration
      • 8.2.4.5.2.3. By End User

9. South America Malignant Mesothelioma Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By End User
  • 9.2.4. By Country
    • 9.2.4.1. Brazil Malignant Mesothelioma Therapeutics Market Outlook
      • 9.2.4.1.1. Market Size & Forecast
      • 9.2.4.1.1.1. By Value
      • 9.2.4.1.2. Market Share & Forecast
      • 9.2.4.1.2.1. By Drug Type
      • 9.2.4.1.2.2. By Route of Administration
      • 9.2.4.1.2.3. By End User
    • 9.2.4.2. Argentina Malignant Mesothelioma Therapeutics Market Outlook
      • 9.2.4.2.1. Market Size & Forecast
      • 9.2.4.2.1.1. By Value
      • 9.2.4.2.2. Market Share & Forecast
      • 9.2.4.2.2.1. By Drug Type
      • 9.2.4.2.2.2. By Route of Administration
      • 9.2.4.2.2.3. By End User
    • 9.2.4.3. Colombia Malignant Mesothelioma Therapeutics Market Outlook
      • 9.2.4.3.1. Market Size & Forecast
      • 9.2.4.3.1.1. By Value
      • 9.2.4.3.2. Market Share & Forecast
      • 9.2.4.3.2.1. By Drug Type
      • 9.2.4.3.2.2. By Route of Administration
      • 9.2.4.3.2.3. By End User

10. Middle East & Africa Malignant Mesothelioma Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By
  • 10.2.4. By End User
  • 10.2.5. By Country
    • 10.2.5.1. South Africa Malignant Mesothelioma Therapeutics Market Outlook
      • 10.2.5.1.1. Market Size & Forecast
      • 10.2.5.1.1.1. By Value
      • 10.2.5.1.2. Market Share & Forecast
      • 10.2.5.1.2.1. By Drug Type
      • 10.2.5.1.2.2. By Route of Administration
      • 10.2.5.1.2.3. By End User
    • 10.2.5.2. Saudi Arabia Malignant Mesothelioma Therapeutics Market Outlook
      • 10.2.5.2.1. Market Size & Forecast
      • 10.2.5.2.1.1. By Value
      • 10.2.5.2.2. Market Share & Forecast
      • 10.2.5.2.2.1. By Drug Type
      • 10.2.5.2.2.2. By Route of Administration
      • 10.2.5.2.2.3. By End User
    • 10.2.5.3. UAE Malignant Mesothelioma Therapeutics Market Outlook
      • 10.2.5.3.1. Market Size & Forecast
      • 10.2.5.3.1.1. By Value
      • 10.2.5.3.2. Market Share & Forecast
      • 10.2.5.3.2.1. By Drug Type
      • 10.2.5.3.2.2. By Route of Administration
      • 10.2.5.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Technology Launches

13. Competitive Landscape

• 13.1. Dr. Reddy's Laboratories Ltd.
  • 13.1.1. Business Overview
  • 13.1.2. Patient Offerings
  • 13.1.3. Recent Developments
  • 13.1.4. Key Personnel
  • 13.1.5. SWOT Analysis
• 13.2. Wellona Pharmaceuticals pvt ltd.
• 13.3. Bristol-Myers Squibb Company
• 13.4. Novocure GmbH
• 13.5. Eli Lilly and Company
• 13.6. Merck Kgaa
• 13.7. Manus Aktteva Biopharma LLP
• 13.8. Pfizer inc.
• 13.9. Ono Pharmaceuticals Co., Ltd

14. Strategic Recommendations

About us & Disclaimer